Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.
One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A).
The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.
[citation needed] This drug was developed by Genentech/Roche.
[citation needed] This monoclonal antibody–related article is a stub.